BR112022022753A2 - Métodos de fabricação de um composto bifuncional, formas ultrapuras do composto bifuncional e formas de dosagem compreendendo o mesmo - Google Patents
Métodos de fabricação de um composto bifuncional, formas ultrapuras do composto bifuncional e formas de dosagem compreendendo o mesmoInfo
- Publication number
- BR112022022753A2 BR112022022753A2 BR112022022753A BR112022022753A BR112022022753A2 BR 112022022753 A2 BR112022022753 A2 BR 112022022753A2 BR 112022022753 A BR112022022753 A BR 112022022753A BR 112022022753 A BR112022022753 A BR 112022022753A BR 112022022753 A2 BR112022022753 A2 BR 112022022753A2
- Authority
- BR
- Brazil
- Prior art keywords
- forms
- compound
- bifunctional compound
- ultrapure
- methods
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126062 Compound A Drugs 0.000 abstract 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CLCTZVRHDOAUGJ-UHFFFAOYSA-N N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide Chemical compound FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=CC=C(N=N3)C(=O)NC3CCC(CC3)OC3=CC(Cl)=C(C=C3)C#N)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O CLCTZVRHDOAUGJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
MÉTODOS DE FABRICAÇÃO DE UM COMPOSTO BIFUNCIONAL, FORMAS ULTRAPURAS DO COMPOSTO BIFUNCIONAL E FORMAS DE DOSAGEM COMPREENDENDO O MESMO. A presente divulgação refere-se a formas ultrapuras, polimorfos, formas amorfas e formulações de N-[(1r,4r)-4-(3-cloro-4-cianofenoxi)ciclohexil]-6-[4-({4- [2-(2,6-dioxopiperidin-3-il)-6-fluoro-1,3-dioxo-2,3-di-hidro-1H-isoindol-5-il]piperazin-1-il}metil)piperidin-1-il]piridazina-3-carboxamida, aqui referido como Composto A: (Composto A). A presente divulgação também se refere a métodos de fabricação e purificação dos mesmos, bem como intermediários úteis na síntese do Composto A. As formas ultrapuras, polimorfos, formas amorfas e formulações do Composto A podem ser usadas como agentes terapêuticos para o tratamento de várias doenças e condições, como o câncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022475P | 2020-05-09 | 2020-05-09 | |
| US202163149143P | 2021-02-12 | 2021-02-12 | |
| US202163177378P | 2021-04-20 | 2021-04-20 | |
| PCT/US2021/031091 WO2021231174A1 (en) | 2020-05-09 | 2021-05-06 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022753A2 true BR112022022753A2 (pt) | 2023-02-14 |
Family
ID=76305987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022753A BR112022022753A2 (pt) | 2020-05-09 | 2021-05-06 | Métodos de fabricação de um composto bifuncional, formas ultrapuras do composto bifuncional e formas de dosagem compreendendo o mesmo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230012321A1 (pt) |
| EP (1) | EP4146642A1 (pt) |
| JP (1) | JP2023524599A (pt) |
| KR (1) | KR20230015933A (pt) |
| CN (1) | CN115996918A (pt) |
| AU (1) | AU2021273458A1 (pt) |
| BR (1) | BR112022022753A2 (pt) |
| CA (1) | CA3181782A1 (pt) |
| CL (1) | CL2023000074A1 (pt) |
| CO (1) | CO2022017700A2 (pt) |
| CR (1) | CR20220630A (pt) |
| EC (1) | ECSP22086223A (pt) |
| IL (1) | IL297762A (pt) |
| MX (1) | MX2022014071A (pt) |
| PE (1) | PE20231204A1 (pt) |
| TW (1) | TW202208345A (pt) |
| WO (1) | WO2021231174A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230414T1 (hr) | 2016-10-11 | 2023-07-07 | Arvinas Operations, Inc. | Spojevi i postupci za ciljanu razgradnju androgenog receptora |
| WO2023025268A1 (zh) * | 2021-08-27 | 2023-03-02 | 苏州晶云药物科技股份有限公司 | 哒嗪甲酰胺类化合物的晶型及其制备方法 |
| WO2023143427A1 (zh) * | 2022-01-27 | 2023-08-03 | 杭州领业医药科技有限公司 | Arv-110的晶型及其制备方法和用途 |
| WO2023205481A1 (en) | 2022-04-21 | 2023-10-26 | Arvinas Operations, Inc. | A combination for use in treating prostate cancer comprising arv-100 and abiraterone |
| CN116282055A (zh) * | 2023-04-04 | 2023-06-23 | 昆明理工大学 | 一种利用酸淬提纯和改性无定形硼粉的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10584A (en) | 1854-02-28 | Bank-lock | ||
| US101A (en) | 1836-12-06 | Method of jcakibtg and furling iw sails fob ships | ||
| ES2588429T3 (es) | 2009-03-09 | 2016-11-02 | Spi Pharma, Inc. | Excipientes y sistemas de excipientes de compresión directa altamente compactables y durables |
| HRP20230414T1 (hr) * | 2016-10-11 | 2023-07-07 | Arvinas Operations, Inc. | Spojevi i postupci za ciljanu razgradnju androgenog receptora |
| KR20220004100A (ko) * | 2019-04-18 | 2022-01-11 | 하이노바 파마슈티컬스 인코포레이티드 | 안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도 |
| US20210113557A1 (en) | 2019-10-22 | 2021-04-22 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
-
2021
- 2021-05-06 KR KR1020227043345A patent/KR20230015933A/ko active Search and Examination
- 2021-05-06 CR CR20220630A patent/CR20220630A/es unknown
- 2021-05-06 US US17/313,679 patent/US20230012321A1/en active Pending
- 2021-05-06 TW TW110116400A patent/TW202208345A/zh unknown
- 2021-05-06 CA CA3181782A patent/CA3181782A1/en active Pending
- 2021-05-06 AU AU2021273458A patent/AU2021273458A1/en active Pending
- 2021-05-06 BR BR112022022753A patent/BR112022022753A2/pt not_active Application Discontinuation
- 2021-05-06 IL IL297762A patent/IL297762A/en unknown
- 2021-05-06 PE PE2022002608A patent/PE20231204A1/es unknown
- 2021-05-06 JP JP2022567864A patent/JP2023524599A/ja active Pending
- 2021-05-06 WO PCT/US2021/031091 patent/WO2021231174A1/en active Application Filing
- 2021-05-06 MX MX2022014071A patent/MX2022014071A/es unknown
- 2021-05-06 EP EP21730706.5A patent/EP4146642A1/en active Pending
- 2021-05-06 CN CN202180045441.1A patent/CN115996918A/zh active Pending
-
2022
- 2022-11-09 EC ECSENADI202286223A patent/ECSP22086223A/es unknown
- 2022-12-06 CO CONC2022/0017700A patent/CO2022017700A2/es unknown
-
2023
- 2023-01-06 CL CL2023000074A patent/CL2023000074A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220630A (es) | 2023-01-23 |
| WO2021231174A1 (en) | 2021-11-18 |
| CN115996918A (zh) | 2023-04-21 |
| TW202208345A (zh) | 2022-03-01 |
| EP4146642A1 (en) | 2023-03-15 |
| AU2021273458A1 (en) | 2022-12-01 |
| US20230012321A1 (en) | 2023-01-12 |
| MX2022014071A (es) | 2023-01-30 |
| CA3181782A1 (en) | 2021-11-18 |
| PE20231204A1 (es) | 2023-08-17 |
| ECSP22086223A (es) | 2022-12-30 |
| KR20230015933A (ko) | 2023-01-31 |
| JP2023524599A (ja) | 2023-06-12 |
| CL2023000074A1 (es) | 2023-07-07 |
| CO2022017700A2 (es) | 2022-12-20 |
| IL297762A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022753A2 (pt) | Métodos de fabricação de um composto bifuncional, formas ultrapuras do composto bifuncional e formas de dosagem compreendendo o mesmo | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP2018502877A5 (pt) | ||
| PE20090547A1 (es) | DERIVADOS DE PIRAZINONA COMO INHIBIDORES DE p38 QUINASA | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| AR051945A1 (es) | Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol | |
| MX2010007714A (es) | Piridinas fusionadas activas como inhibidores de c-met. | |
| DOP2002000544A (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino] quinazolin-6-il} alil) acetamida y procedimiento de producción | |
| JP2011504497A5 (pt) | ||
| ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| MA34604B1 (fr) | Derives de la pyrazine en tant que bloqueurs de l'enac | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| HRP20050967B8 (hr) | Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| BRPI0416989A (pt) | derivados aminopirazole como inibidores gsk-3 | |
| NO20091185L (no) | Piperidinderivater | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| UA97660C2 (ru) | Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| PE20210417A1 (es) | Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende | |
| TW200732304A (en) | Piperidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |